trial

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCTId NCT00509067
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 43 (actual)
Sponsored by Georgetown University
Primary completion 2011-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
43 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-11
Primary completion
2011-03
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
GalantamineCDP-cholineAripiprazole

Sponsors

Georgetown UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Washington D.C. Veterans Affairs Medical CenterCollaborator

Investigators

1
Stephen I. Deutsch, PhD, MDPrincipal Investigator

Sites

1 total
Washington D.C., United States

Linked catalysts

1
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophren — primary completion2011-03

Facts & assertions

4 sourced
Enrollment
43
Phase
PHASE2
Primary Completion Date
2011-03
Status
COMPLETED
relationships
The graph out of here
drug
Galantamine
drug
CDP-choline
drug
Aripiprazole
drug
lead_sponsor
Georgetown University
company
collaborator
National Institute of Mental Health (NIMH)
company
Washington D.C. Veterans Affairs Medical Center
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Stephen I. Deutsch, PhD, MD
person